Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|June 2, 2003
- Pharmaceutical Technology-06-02-2003
- Volume 27
- Issue 6
Behavior of Uptake of Moisture by Drugs and Excipients under Accelerated Conditions of Temperature and Humidity in the Absence and the Presence of Light
Author(s)Saranjit Singh
The authors investigated the moisture gain of products containing ethambutol that were packaged in strip and blister packs as well as unpackaged formulations.
Advertisement
Articles in this issue
over 23 years ago
June 2003over 23 years ago
From Genome Exploration to Drug Developmentover 23 years ago
Are you ready for Gen3over 23 years ago
Formulation Development of a Nucleotide Phosphoramidateover 23 years ago
Outsourcing OutlookAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
Advertisement
Advertisement